

MedGenome to Present on OncoPept - a Point Solution in Cancer Immunotherapy at the Novel Immunotherapeutics Summit 2016

Tue January 12, 2016 7:00 AM | PR Newswire

SAN FRANCISCO, January 12, 2016 /PRNewswire/ --

Our Analysis Reveals That Tongue and Buccal Cancers Harbor a set of Dual-purpose Tumor Neo-antigens That can be Used as Cancer Vaccines in a Therapeutic Setting, and as Biomarkers of Response to Select Patients for Cancer Immunotherapy

MedGenome will present results from their Head & Neck cancer study in which published genomics data from over 400 Head & Neck cancer samples have been analyzed to identify potential vaccine candidates using MedGenome's proprietary OncoPept platform at the Novel Immunotherapeutics Summit 2016, on January 25-26, 2016 at San Diego, CA .

(Logo: <http://photos.prnewswire.com/prnh/20160112/784044>)

The analysis shows that differential gene expression between tongue and buccal cancers produce both unique and shared vaccine candidates that can be used in combination therapies. Several studies have shown that the efficacy and durability of response to the checkpoint control inhibitors, which complement the traditional approach of targeting driver genes in cancer, are significantly enhanced by combining vaccine candidates derived from neo-antigens expressed by the tumor cells.

MedGenome's OncoPept is an integrated platform that uses exome sequencing, RNA sequencing and computational methods to characterize tumor neo-antigens, analyze T-cell neo-epitopes and reveal gene expression signatures. The platform has various pre-clinical and clinical research applications.

About MedGenome:

MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Our powerful genomics solutions accelerate drug discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare. MedGenome is the market leader for genetic diagnostic testing in India and has worked with thousands of doctors, hospitals, and patients across India by applying Next Generation Sequencing (NGS) techniques to large disease cohorts in cancer, eye and neurological disorders, diabetes, cardiovascular diseases and rare cancers.

For more information, visit us at <http://www.medgenome.com>

SEEKING ALPHA PRODUCT UPDATES

- **Contest: Your Best Short Idea For 2016** by SA Editor Daniel Shvartsman

DIVIDENDS & INCOME

1. **Sell Everything: Cut Your Income Off To Spite Your Retirement** by George Schneider
2. **NorthStar Realty Finance External Manager NSAM Hires Goldman Sachs - Time To Double Down?** by Bill Stoller
3. **Mr. Market Likes This REIT That Owns Buildings Leased To Uncle Sam** by Brad Thomas
4. **AT&T: Game Changer** by Christopher F. Davis

ETFs & PORTFOLIO STRATEGY

1. **1704 On The S&P 500 In 2016? Less Far-Fetched Than Investors Want To Believe** by Gary Gordon
2. **Limiting Losses On Tesla Stock** by David Pinsen
3. **3 Ideas Never Before Seen (Together)** by Chris DeMuth Jr.
4. **The Vanguard Dividend Appreciation ETF Is On Sale** by ColoradoWealthManagementFund

MACRO VIEW

1. **Oil Breaks \$30, Freeport-McMoRan Caves In, Biotechs In Danger - Bezek's Daily Briefing** by Ian Bezek
2. **2016 EM Outlook: Brazil Worst, India Best, We Sort Out The Rest** by Ian Bezek
3. **Container Shipping Market Macro Outlook For 2016** by James Catlin
4. **Pepsi, Challenged?** by Chris DeMuth Jr.